Compare VENUS REMEDIES with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES FULFORD INDIA VENUS REMEDIES/
FULFORD INDIA
 
P/E (TTM) x -13.7 398.8 - View Chart
P/BV x 0.9 6.2 14.8% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 VENUS REMEDIES   FULFORD INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
FULFORD INDIA
Mar-14
VENUS REMEDIES/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs126942 13.4%   
Low Rs61450 13.6%   
Sales per share (Unadj.) Rs301.8691.4 43.7%  
Earnings per share (Unadj.) Rs-24.911.5 -217.0%  
Cash flow per share (Unadj.) Rs2.515.4 16.6%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs293.3380.0 77.2%  
Shares outstanding (eoy) m12.343.90 316.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.0 30.8%   
Avg P/E ratio x-3.860.7 -6.2%  
P/CF ratio (eoy) x36.745.3 81.1%  
Price / Book Value ratio x0.31.8 17.4%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m1,1542,714 42.5%   
No. of employees `0000.90.4 208.3%   
Total wages/salary Rs m393505 77.8%   
Avg. sales/employee Rs Th4,026.16,073.0 66.3%   
Avg. wages/employee Rs Th425.01,137.4 37.4%   
Avg. net profit/employee Rs Th-331.8100.7 -329.6%   
INCOME DATA
Net Sales Rs m3,7242,696 138.1%  
Other income Rs m23125 17.9%   
Total revenues Rs m3,7472,822 132.8%   
Gross profit Rs m395-46 -850.9%  
Depreciation Rs m33815 2,225.7%   
Interest Rs m35410 3,729.5%   
Profit before tax Rs m-27554 -507.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3210 329.2%   
Profit after tax Rs m-30745 -686.6%  
Gross profit margin %10.6-1.7 -616.1%  
Effective tax rate %-11.517.7 -64.9%   
Net profit margin %-8.21.7 -497.1%  
BALANCE SHEET DATA
Current assets Rs m2,6381,738 151.7%   
Current liabilities Rs m2,305545 423.1%   
Net working cap to sales %8.944.3 20.2%  
Current ratio x1.13.2 35.9%  
Inventory Days Days13548 279.4%  
Debtors Days Days464 1,076.3%  
Net fixed assets Rs m4,87112 40,930.8%   
Share capital Rs m12339 316.4%   
"Free" reserves Rs m3,4961,443 242.3%   
Net worth Rs m3,6191,482 244.2%   
Long term debt Rs m1,3740-   
Total assets Rs m7,5092,077 361.6%  
Interest coverage x0.26.7 3.3%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.3 38.2%   
Return on assets %0.62.6 24.2%  
Return on equity %-8.53.0 -281.1%  
Return on capital %1.64.3 36.7%  
Exports to sales %00-   
Imports to sales %13.924.5 56.7%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517659 78.3%   
Fx inflow Rs m017 0.0%   
Fx outflow Rs m517673 76.7%   
Net fx Rs m-517-656 78.7%   
CASH FLOW
From Operations Rs m51490 571.6%  
From Investments Rs m-123105 -117.7%  
From Financial Activity Rs m-387-14 2,745.4%  
Net Cashflow Rs m4181 2.3%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 3.8 4.7%  
FIIs % 0.6 0.1 580.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.2 313.2%  
Shareholders   20,121 4,783 420.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  J.B.CHEMICALS  ORCHID PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 16, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - IPCA LABS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS